lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

BOHOŠOVÁ Júlia KUBÍČKOVÁ Adéla SLABÝ Ondřej

Year of publication 2021
Type Article in Periodical
Magazine / Source Biomolecules
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.mdpi.com/2218-273X/11/5/664
Doi http://dx.doi.org/10.3390/biom11050664
Keywords biomarker; prognosis; diagnosis; long non-coding RNA; tumorigenesis
Description LncRNA PVT1 (plasmacytoma variant translocation 1) has become a staple of the lncRNA profile in patients with renal cell carcinoma (RCC). Common dysregulation in renal tumors outlines the essential role of PVT1 in the development of RCC. There is already a plethora of publications trying to uncover the cellular mechanisms of PVT1-mediated regulation and its potential exploitation in management of RCC. In this review, we summarize the literature focused on PVT1 in RCC and aim to synthesize the current knowledge on its role in the cells of the kidney. Further, we provide an overview of the lncRNA profiling studies that have identified a more or less significant association of PVT1 with the clinical behavior of RCC. Based on our search, we analyzed the 17 scientific papers discussed in this review that provide robust support for the indispensable role of PVT1 in RCC development and future personalized therapy.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.